Jared J Gartner
Overview
Explore the profile of Jared J Gartner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
5032
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hanada K, Zhao C, Gil-Hoyos R, Gartner J, Chow-Parmer C, Lowery F, et al.
Cancer Cell
. 2022 Apr;
40(5):479-493.e6.
PMID: 35452604
A common theme across multiple successful immunotherapies for cancer is the recognition of tumor-specific mutations (neoantigens) by T cells. The rapid discovery of such antigen responses could lead to improved...
12.
Levi S, Copeland A, Nah S, Crystal J, Ivey G, Lalani A, et al.
Clin Cancer Res
. 2022 Mar;
28(14):3042-3052.
PMID: 35247926
Purpose: Immune checkpoint blockade (ICB) agents and adoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TIL) are prominent immunotherapies used for the treatment of advanced melanoma. Both therapies rely on activation...
13.
Lowery F, Krishna S, Yossef R, Parikh N, Chatani P, Zacharakis N, et al.
Science
. 2022 Feb;
375(6583):877-884.
PMID: 35113651
The accurate identification of antitumor T cell receptors (TCRs) represents a major challenge for the engineering of cell-based cancer immunotherapies. By mapping 55 neoantigen-specific TCR clonotypes (NeoTCRs) from 10 metastatic...
14.
Zacharakis N, Huq L, Seitter S, Kim S, Gartner J, Sindiri S, et al.
J Clin Oncol
. 2022 Feb;
40(16):1741-1754.
PMID: 35104158
Purpose: Metastatic breast cancer (mBrCa) is most often an incurable disease with only modest responses to available immunotherapies. This study investigates the immunogenicity of somatic mutations in breast cancer and...
15.
Gartner J, Parkhurst M, Gros A, Tran E, Jafferji M, Copeland A, et al.
Nat Cancer
. 2021 Dec;
2(5):563-574.
PMID: 34927080
Tumor neoepitopes presented by major histocompatibility complex (MHC) class I are recognized by tumor-infiltrating lymphocytes (TIL) and are targeted by adoptive T-cell therapies. Identifying which mutant neoepitopes from tumor cells...
16.
Lu Y, Zheng Z, Lowery F, Gartner J, Prickett T, Robbins P, et al.
J Immunother Cancer
. 2021 Jul;
9(7).
PMID: 34321276
Background: Recognition of neoantigens by T cells plays a major role in cancer immunotherapy. Identification of neoantigen-specific T-cell receptors (TCRs) has become a critical research tool for studying T cell-mediated...
17.
Leko V, Cafri G, Yossef R, Paria B, Hill V, Gurusamy D, et al.
J Immunother Cancer
. 2021 Jul;
9(7).
PMID: 34266885
The adoptive transfer of naturally occurring T cells that recognize cancer neoantigens has led to durable tumor regressions in select patients with cancer. However, it remains unknown whether such T...
18.
Levin N, Paria B, Vale N, Yossef R, Lowery F, Parkhurst M, et al.
Clin Cancer Res
. 2021 Jun;
27(18):5084-5095.
PMID: 34168045
Purpose: Immunotherapies mediate the regression of human tumors through recognition of tumor antigens by immune cells that trigger an immune response. Mutations in the oncogenes occur in about 30% of...
19.
Krishna S, Lowery F, Copeland A, Bahadiroglu E, Mukherjee R, Jia L, et al.
Science
. 2020 Dec;
370(6522):1328-1334.
PMID: 33303615
Adoptive T cell therapy (ACT) using ex vivo-expanded autologous tumor-infiltrating lymphocytes (TILs) can mediate complete regression of certain human cancers. The impact of TIL phenotypes on clinical success of TIL-ACT...
20.
Cafri G, Gartner J, Zaks T, Hopson K, Levin N, Paria B, et al.
J Clin Invest
. 2020 Oct;
130(11):5976-5988.
PMID: 33016924
BACKGROUNDTherapeutic vaccinations against cancer have mainly targeted differentiation antigens, cancer-testis antigens, and overexpressed antigens and have thus far resulted in little clinical benefit. Studies conducted by multiple groups have demonstrated...